Sanofi
Long book
$336.0M
Q1 2026
Positions
9
Top-10 weight
100%
concentration
Last quarter
+46.3%
SPY +14.8%
Turnover
11%
of book per quarter
Strategy in plain words
auto-generated from filingsSanofi is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $336.0M US long book across 9 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: MEIRAGTX HOLDINGS PLC, INHIBRX BIOSCIENCES INC, NOVAVAX INC, ANAPTYSBIO INC, AGOMAB THERAPEUTICS NV.
Over the last 6 quarters its long book ran on average 13.1pp per quarter ahead of the S&P 500, beating the index in 5 of 6 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-0.7%
Q1 2025
-0.8%
Q2 2025
+40.4%
Q3 2025
+17.6%
Q4 2025
+3.7%
Q1 2026
+46.3%
Sector allocation
Healthcare 100%
Long book by quarter
What does Sanofi own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| MGTX MEIRAGTX HOLDINGS PLC | Healthcare | 12.2M | $105.6M | 31.4% | Held |
| INBX INHIBRX BIOSCIENCES INC | Healthcare | 1.2M | $77.8M | 23.2% | Held |
| NVAX NOVAVAX INC | Healthcare | 6.9M | $56.0M | 16.7% | Held |
| ANAB ANAPTYSBIO INC | Healthcare | 821.9K | $30.4M | 9.0% | Held |
| MPLT MAPLIGHT THERAPEUTICS INC | Healthcare | 912.0K | $18.5M | 5.5% | Held |
| IMRX IMMUNEERING CORP - CLASS A | Healthcare | 2.7M | $14.3M | 4.2% | Held |
| ELDN ELEDON PHARMACEUTICALS INC | Healthcare | 815.0K | $2.5M | 0.7% | Held |
| QTTB Q32 BIO INC | Healthcare | 244.1K | $1.6M | 0.5% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 7, 2026 | 9 | $336.0M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 11, 2026 | 8 | $310.4M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 4, 2025 | 9 | $260.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Jul 29, 2025 | 10 | $175.7M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 6, 2025 | 9 | $165.9M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 9 | $174.4M | canonical | SEC ↗ |